<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pertussis infection in infants and children: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pertussis infection in infants and children: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pertussis infection in infants and children: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia Yeh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment and prevention of pertussis (whooping cough) infection in infants and children will be discussed here. The clinical presentation, including complications, and the diagnosis of pertussis in infants and children; the microbiology, epidemiology, and pathogenesis of pertussis infection; and the clinical features, treatment, and prevention of pertussis in adolescents and adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8043.html" rel="external">"Pertussis infection: Epidemiology, microbiology, and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8045.html" rel="external">"Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H94180645"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>Pertussis infection often results in a protracted illness. Frequent coughing paroxysms interfere with daily function. Young infants can develop serious complications, including poor weight gain, apnea, pneumonia, respiratory failure, seizures, and death. Without antimicrobial therapy, the child is contagious throughout much of the protracted illness. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H90991858"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management recommendations below are generally consistent with those of the United States Centers for Disease Control and Prevention [<a href="#rid1">1</a>] and the American Academy of Pediatrics [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3808494308"><span class="h2">Hospitalization</span></p><p class="headingAnchor" id="H36861918"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Indications for hospitalization in infants and children with pertussis infection or suspected pertussis infection include [<a href="#rid3">3-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory distress, manifested by tachypnea, retractions, nasal flaring, grunting, and the use of accessory muscles</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of pneumonia (see  <a class="medical medical_review" href="/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to feed</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cyanosis or apnea, with or without coughing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;4 months (see <a class="local">'Special population: Infants &lt;4 months'</a> below)</p><p></p><p class="headingAnchor" id="H3393904907"><span class="h3">Isolation</span><span class="headingEndMark"> — </span>Standard precautions, as well as droplet precautions (mask within 3 feet), are recommended for children with pertussis who are admitted to the hospital [<a href="#rid2">2</a>]. These precautions should be in effect until five days of effective therapy have been administered or 21 days after the onset of symptoms in untreated patients. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a>.)</p><p>Contact precautions are not necessary for <em>B. pertussis</em> but may be indicated for other conditions in the differential diagnosis until a diagnosis is confirmed (eg, respiratory syncytial virus, adenovirus, parainfluenza virus). (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p class="headingAnchor" id="H2546633591"><span class="h3">Discharge criteria</span><span class="headingEndMark"> — </span><strong>Minimum</strong> criteria for discharge include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ability to tolerate coughing episodes without becoming hypoxic and/or bradycardic; most infants who are admitted to the hospital with pertussis continue to have coughing paroxysms after discharge</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ability to eat enough to gain weight</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reliable caretakers who are comfortable caring for the child at home</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assurance of close outpatient follow-up</p><p></p><p class="headingAnchor" id="H2"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive care is the mainstay of management for <em>Bordetella pertussis</em> infection.</p><p class="headingAnchor" id="H4"><span class="h3">Fluids and nutrition</span><span class="headingEndMark"> — </span>Infants and children with frequent paroxysms of cough may have increased fluid and energy needs, which can be difficult to meet if the infant is coughing or vomiting. The child's fluid and nutritional status should be monitored closely, whether the child is admitted to the hospital or cared for at home.</p><p>Intravenous hydration and nasogastric feeding may be required for some hospitalized patients. The nasogastric tube may stimulate the cough reflex in some infants; however, nasogastric feedings should be attempted before parenteral nutrition for infants who are unable to gain weight because of severe coughing paroxysms.</p><p class="headingAnchor" id="H939470078"><span class="h3">Management of cough</span><span class="headingEndMark"> — </span>The paroxysmal cough of pertussis may be severe and protracted; it is the main cause of morbidity from pertussis. Known triggers for coughing paroxysms (eg, exercise, cold temperatures, nasopharyngeal [NP] suctioning) should be avoided if possible – although NP suctioning may be necessary for diagnosis. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Laboratory confirmation'</a>.)</p><p>We do not suggest symptomatic therapies for pertussis-related cough. In small trials and a systematic review, symptomatic treatments, including bronchodilators, corticosteroids, antihistamines, and antitussive agents, have not been proven to be beneficial in patients with pertussis [<a href="#rid6">6-10</a>]. In general, the risks of these therapies outweigh the benefits, particularly for opioid cough suppressants, which may adversely affect respiration. However, based on anecdotal experience, some clinicians may attempt a trial of inhaled beta-agonists for infants with compromised respiratory status. Although pertussis-associated cough did not improve in two small trials (total of 34 patients) [<a href="#rid7">7,8</a>], increased risks of beta-agonists in patients with pertussis have not been reported.</p><p class="headingAnchor" id="H6"><span class="h2">Antimicrobial therapy</span></p><p class="headingAnchor" id="H8"><span class="h3">Indications</span><span class="headingEndMark"> — </span>When administered early in the course (ie, within seven days of symptom onset), antimicrobial therapy for pertussis may shorten the duration of symptoms and decrease transmission to susceptible contacts [<a href="#rid11">11,12</a>]. Treatment is particularly important for infants &lt;6 months because they are at increased risk for complications. In addition, if not treated, they remain culture positive for longer periods than do older children and adults [<a href="#rid13">13-15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We recommend antimicrobial treatment for individuals who have <em>B. pertussis</em> isolated from pertussis cultures or positive polymerase chain reaction (PCR) within three weeks of cough onset (individuals &gt;1 year) or six weeks of cough onset (individuals &lt;1 year) [<a href="#rid1">1,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also recommend treatment for infants and children with a clinical diagnosis of pertussis (with or without laboratory confirmation) who have had symptoms &lt;21 days. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Clinical diagnosis'</a>.)</p><p></p><p class="bulletIndent1">Antimicrobial therapy should be initiated based upon clinical suspicion and not on laboratory confirmation, because laboratory confirmation may take up to one week, depending on the laboratory facilities and testing methods that are available. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Laboratory confirmation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial therapy also may be indicated for patients who have had &gt;21 days of symptoms, particularly those who are likely to be in contact with high-risk individuals [<a href="#rid17">17,18</a>], although the utility of therapy in such patients is less clear than for patients with &lt;21 days of symptoms.</p><p></p><p>Early treatment (ie, within seven days of symptom onset) may decrease the severity of symptoms [<a href="#rid19">19</a>]. However, most patients do not come to medical attention until the paroxysmal phase, which occurs one to two weeks after illness onset. Clinical trials and observational studies of treatment during the paroxysmal stage have yielded inconsistent results regarding the ability of treatment to alter the clinical course [<a href="#rid20">20-23</a>]. A systematic review of randomized and quasi-randomized trials of antibiotics for the treatment of pertussis concluded that antibiotic treatment does not alter the clinical course [<a href="#rid12">12</a>]. However, in many of the studies that were included, treatment was initiated after the paroxysmal phase.</p><p>Patients are most contagious during the catarrhal stage and through the first three weeks after onset of coughing spells or until five days after initiation of appropriate treatment [<a href="#rid2">2</a>]. A systematic review of randomized and quasi-randomized trials of antibiotics concluded that antibiotic treatment is effective in eradicating pertussis from the nasopharynx, thereby reducing the risk of transmission [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Choice of regimen</span><span class="headingEndMark"> — </span>The macrolide antibiotics, <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a>, <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a>, and <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a> are the preferred antimicrobial therapies for the treatment of pertussis [<a href="#rid1">1,2,24</a>]. Macrolide-resistant <em>B. pertussis</em> is rare but has been reported in China [<a href="#rid25">25-27</a>], Iran [<a href="#rid28">28,29</a>], and France [<a href="#rid30">30</a>]. The preferred regimen varies with age  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>) [<a href="#rid1">1,21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants younger than one month</strong> – <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">Azithromycin</a> is the recommended macrolide antibiotic for the treatment of pertussis in infants younger than one month of age. It is preferred over <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a>; <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a> is not recommended.</p><p></p><p class="bulletIndent1">Both <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> and <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a> are associated with increased risk of infantile hypertrophic pyloric stenosis (IHPS), particularly in infants younger than two weeks [<a href="#rid31">31-36</a>]. The risk of IHPS with <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a> is not known [<a href="#rid37">37</a>]. IHPS should be considered in young infants who develop vomiting within one month of therapy with a macrolide antibiotic given in the first month of life. Cases of pyloric stenosis associated with oral macrolide antibiotics should be reported to the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;token=xvyaImDcLZQw%2FKZaoXWwxUDhBq6SPMBQbzrmFLdvw6uLInTYq0WEZZE23nYfEJdpji3bziSW87ksfkpGSKeZ%2FC4BVOKV%2FWdosDZdfOoBdep7W5s6oZowZkx4dccnetNU&amp;TOPIC_ID=5997" target="_blank">US Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program</a>. (See  <a class="medical medical_review" href="/d/html/5890.html" rel="external">"Infantile hypertrophic pyloric stenosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants and children older than one month</strong> – Any of the macrolide antibiotics  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>) can be used for the treatment of pertussis in infants and children older than one month of age. Neither <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> nor <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a> is licensed by the FDA for use in infants younger than six months; however, azithromycin is commonly employed for pertussis treatment and prophylaxis in young infants.</p><p></p><p><a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">Azithromycin</a> and <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a> have a more convenient dosing schedule than <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a> and are better tolerated [<a href="#rid38">38,39</a>]. Azithromycin and clarithromycin have excellent in vitro activity and have been evaluated in several clinical trials [<a href="#rid39">39-42</a>]. In the largest trial, 477 children with confirmed or suspected pertussis were randomly assigned to treatment with erythromycin or azithromycin [<a href="#rid39">39</a>]. Pertussis was eradicated from the nasopharynx of children who had positive cultures (24 percent of the total), regardless of which antibiotic they received. However, 90 percent of children who took azithromycin completed therapy, compared with 55 percent who took erythromycin.</p><p><a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is an alternative for children older than two months who have a contraindication to or cannot tolerate macrolide agents or are infected with a strain that is macrolide resistant [<a href="#rid2">2</a>]. TMP-SMX should not be used in infants younger than two months of age because of the potential risk of kernicterus related to bilirubin displacement.</p><p>Beta-lactam antibiotics (<a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a>, <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a>, cephalosporins) have variable activity against <em>B. pertussis</em> and are not recommended. Ampicillin and amoxicillin do not eradicate <em>B. pertussis</em> from the nasopharynx [<a href="#rid43">43</a>]. Neither <a class="drug drug_pediatric" data-topicid="12830" href="/d/drug information/12830.html" rel="external">tetracycline</a> nor fluoroquinolone antibiotics are recommended for use in young children because of potential adverse effects. (See  <a class="medical medical_review" href="/d/html/494.html" rel="external">"Tetracyclines", section on 'Adverse reactions'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a>.)</p><p class="headingAnchor" id="H2656794870"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of therapy depends upon the agent  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>). We suggest 5 days for <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a>, 14 days for <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a>, 7 days for <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a>, and 14 days for <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a>.</p><p>A meta-analysis evaluated randomized and quasi-randomized controlled trials of antibiotics for the treatment of pertussis that compared short-term (<a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> for three days, <a class="drug drug_pediatric" data-topicid="13165" href="/d/drug information/13165.html" rel="external">clarithromycin</a> for seven days, or <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a> estolate for seven days) and long-term macrolide therapy (erythromycin estolate or erythromycin for 14 days) for the eradication of <em>B. pertussis</em> from the nasopharynx [<a href="#rid12">12</a>]. The report concluded that short-term therapy was as effective and associated with significantly fewer side effects. However, we continue to suggest a 14-day course of erythromycin, because relapses have been reported after courses of 7 to 10 days [<a href="#rid44">44</a>]. We also continue to suggest a five-day course of azithromycin, because the number of subjects treated with the shorter duration of azithromycin in the meta-analysis was small (&lt;20 subjects) [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H90992297"><span class="h2">Special population: Infants &lt;4 months</span><span class="headingEndMark"> — </span>The recommendations in this section are consistent with guidance provided by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdph.ca.gov%2FPrograms%2FCID%2FDCDC%2FPages%2FImmunization%2Fpertussis.aspx&amp;token=YXVx7qSYWdpODmpLx16x6TItHyB6PTBIrfD%2Fbq2dOOHltnFKVrXpMBIHzWDSQBZ0tiRvxxTfCBmxcNv2nUhYGIkNF6TRozwCrJaEl%2F05%2Fuk%3D&amp;TOPIC_ID=5997" target="_blank">California Department of Public Health</a> (DPH) and several California pediatric infectious disease experts based upon their experience with severe pertussis in young infants during the 2010 and 2014 outbreaks [<a href="#rid5">5,45</a>].</p><p class="headingAnchor" id="H90992982"><span class="h3">Treatment setting</span><span class="headingEndMark"> — </span>Age &lt;4 months is an indication for hospitalization in infants with pertussis or suspected pertussis infection given the concerns for rapid deterioration. Infants younger than four months are at increased risk for severe or fatal pertussis infection [<a href="#rid45">45-47</a>]. In a review of 53 fatal cases of pertussis in infants younger than four months from a single state (1998 to 2014), the case fatality rate was 1.2 percent; 47 of the infants were younger than two months at the time of illness onset [<a href="#rid48">48</a>].</p><p>The preadmission evaluation of infants &lt;4 months with suspected pertussis typically includes a complete blood count with differential. It is discussed separately. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p>Hospitalization at a medical center with a pediatric intensive care unit is suggested for infants younger than four months of age and white blood cell (WBC) count &gt;30,000 cell/microL (which is associated with significant morbidity [<a href="#rid45">45,48-50</a>]) [<a href="#rid5">5</a>]. The severity of illness in young infants is unpredictable; clinical decline may occur rapidly and without warning [<a href="#rid51">51</a>]. Intensive care may be required for the management of apnea, seizures, respiratory failure, pulmonary hypertension, and/or cardiac failure. If the admitting hospital cannot provide intensive care, transfer to a hospital with an intensive care unit may be warranted [<a href="#rid5">5</a>]. (See <a class="local">'Critically ill infants'</a> below.)</p><p class="headingAnchor" id="H90992989"><span class="h3">Antimicrobial therapy</span><span class="headingEndMark"> — </span>Antimicrobial therapy for pertussis in infants &lt;4 months of age should be initiated immediately upon suspicion of pertussis  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>) [<a href="#rid5">5,45</a>]. Laboratory confirmation should not delay the initiation of treatment. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Infants &lt;4 months'</a> and <a class="local">'Antimicrobial therapy'</a> above.)</p><p class="headingAnchor" id="H90992996"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>The respiratory rate, heart rate, oxygen saturation, and WBC count of infants who are admitted to the hospital for pertussis (suspected or confirmed) should be monitored. For infants younger than four months, some experts [<a href="#rid45">45</a>] suggest continuous cardiorespiratory monitoring and WBC count every 12 hours with transfer to the pediatric intensive care unit if the WBC count increased by ≥50 percent in 24 hours [<a href="#rid45">45</a>]. For infants ≤60 days of age, they also suggest chest radiography to evaluate pneumonia and echocardiography to evaluate pulmonary hypertension.</p><p>Case series suggest that exchange transfusion or leukapheresis may be helpful in the management of pertussis-related respiratory failure, pulmonary hypertension, and cardiac failure [<a href="#rid52">52-57</a>], but it must be performed <strong>before</strong> the infant is in severe distress or has multiorgan failure [<a href="#rid48">48,56</a>]. (See <a class="local">'Critically ill infants'</a> below.)</p><p>Documentation of oral intake and the severity of coughing spells (eg, whether they are associated with hypoxia or bradycardia) and apneic episodes are helpful in discharge planning. The frequency of coughing spells and apnea decrease before severity; thus, discharge decisions should be based upon the severity of coughing spells and apnea rather than the frequency [<a href="#rid5">5</a>]. (See <a class="local">'Discharge criteria'</a> above.)</p><p class="headingAnchor" id="H90992676"><span class="h3">Critically ill infants</span><span class="headingEndMark"> — </span>Critically ill infants include those with apnea, seizures, or pneumonia complicated by respiratory failure, pulmonary hypertension, and/or cardiac failure. Complicated pneumonia usually occurs in association with WBC count ≥30,000 cells/microL [<a href="#rid48">48</a>].</p><p>A full discussion of the intensive care management of infants with pertussis is beyond the scope of this review. Guidelines for the intensive care unit management of infants with pertussis are provided by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdph.ca.gov%2FPrograms%2FCID%2FDCDC%2FPages%2FImmunization%2Fpertussis.aspx&amp;token=YXVx7qSYWdpODmpLx16x6TItHyB6PTBIrfD%2Fbq2dOOHltnFKVrXpMBIHzWDSQBZ0tiRvxxTfCBmxcNv2nUhYGIkNF6TRozwCrJaEl%2F05%2Fuk%3D&amp;TOPIC_ID=5997" target="_blank">California DPH</a>, and summarized below. Management or consultation with an intensivist may be most appropriate in these instances.</p><p class="bulletIndent1"><span class="glyph">●</span>Apnea – Infants with significant apnea (eg, if adequate ventilation is a concern) may require mechanical ventilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures – Seizures in infants with pertussis are treated in the same manner as seizures due to other causes. (See  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia complicated by refractory hypoxemia, pulmonary hypertension, and/or cardiac failure – This scenario is typically associated with extreme leukocytosis and has a mortality of up to 80 percent [<a href="#rid47">47,48,57,58</a>]. In young infants with pertussis, WBC count ≥30,000 cells/microL has been associated with increased severity and death.</p><p></p><p class="bulletIndent1">Based on the California outbreak experience, some infectious disease experts suggest exchange transfusion for infants with pertussis who are younger than four months and have <strong>any</strong> of the following [<a href="#rid5">5,45,48,56,58</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>WBC count ≥25,000/microL with lymphocyte count ≥12,000/microL and <strong>one or more</strong> of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cardiogenic shock</p><p class="bulletIndent3"><span class="glyph">-</span>Pulmonary hypertension</p><p class="bulletIndent3"><span class="glyph">-</span>Organ failure (eg, renal failure)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total WBC ≥48,000/microL with lymphocyte count ≥15,000/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total WBC ≥30,000/microL with lymphocyte count ≥15,000/microL if the rate of rise was ≥50 percent in 24 hours</p><p></p><p class="bulletIndent1">Additional indications for exchange transfusion include pulse rate consistently &gt;170 beats/minute, respiratory rate consistently &gt;70 breaths/minute, and oxygen saturation of &lt;80 percent [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">Given the potential for severe or fatal pertussis infection in young infants, the recommendations above have been generalized to all infants based upon observational data in infants &lt;4 months of age who were admitted to an intensive care unit. In case series, hypoxemia, pulmonary hypertension, and cardiac failure that were unresponsive to other measures improved after exchange transfusion [<a href="#rid52">52-56</a>]. In a 2014 literature review of 47 reported cases of critical pertussis treated with exchange transfusion, 30 (64 percent) survived [<a href="#rid59">59</a>]. The technique for double volume exchange transfusion is the same as that used for newborns with hyperbilirubinemia [<a href="#rid5">5,60</a>]. (See  <a class="medical medical_review" href="/d/html/121592.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care", section on 'Exchange transfusion'</a>.)</p><p></p><p class="bulletIndent1">For infants who do not improve with exchange transfusion, extracorporeal membrane oxygenation (ECMO) may be warranted as a life-saving measure; however, in a review of 61 children with pertussis who were treated with ECMO, the mortality rate was 70.5 percent [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">Given the sparsity of data, consultation with an experienced pediatric intensivist is suggested before undertaking exchange transfusion or ECMO for the treatment of pertussis in young infants.</p><p></p><p class="headingAnchor" id="H90991851"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The prevention recommendations below are generally consistent with those of the United States Centers for Disease Control and Prevention [<a href="#rid1">1</a>] and the American Academy of Pediatrics [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Postexposure prophylaxis</span></p><p class="headingAnchor" id="H16"><span class="h3">Indications and timing</span><span class="headingEndMark"> — </span>We suggest postexposure antimicrobial prophylaxis for all household and close contacts of the index case and for exposed individuals at high risk for severe or complicated pertussis, even if the exposed person is fully immunized. Postexposure prophylaxis is most effective when initiated within 21 days of the onset of cough in the index patient [<a href="#rid1">1</a>]. The utility of postexposure prophylaxis after 21 days of onset of cough in the index case is unclear.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Close contacts</strong> – Close contacts are defined by [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Living in the same household</p><p class="bulletIndent2"><span class="glyph">•</span>Face-to-face exposure within 3 feet of a symptomatic patient</p><p class="bulletIndent2"><span class="glyph">•</span>Direct contact with respiratory, oral, or nasal secretions from a symptomatic patient</p><p class="bulletIndent2"><span class="glyph">•</span>Sharing the same confined space in close proximity with a symptomatic patient for ≥1 hour</p><p></p><p class="bulletIndent1">Local public health officials should be consulted for recommendations regarding control of pertussis in schools. Prophylaxis for entire schools or classrooms usually is not recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> – Individuals who should receive postexposure prophylaxis because they are at high risk for severe or complicated pertussis or they may expose individuals who are at high risk include [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants younger than one year, particularly those younger than four months</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnant women</p><p class="bulletIndent2"><span class="glyph">•</span>Persons with immunodeficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Persons with underlying medical conditions (chronic lung disease, respiratory insufficiency, cystic fibrosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Persons who have contact with infants</p><p></p><p>Factors to consider in decisions about postexposure prophylaxis include the contagiousness of the patient, the intensity of the exposure, the potential for consequences of severe pertussis in the contact, and the possibility for secondary exposure of persons at high risk of severe infection from the contact [<a href="#rid1">1</a>]. The benefits of prophylaxis must be weighed against the potential adverse effects. (See <a class="local">'Choice of regimen'</a> above.)</p><p>It is not necessary for asymptomatic contacts who are receiving antimicrobial prophylaxis to avoid contact with high-risk individuals [<a href="#rid61">61</a>]. Symptomatic contacts who are receiving antimicrobial prophylaxis should avoid contact with high-risk individuals until they have completed five days of antimicrobial prophylaxis. </p><p>Retrospective epidemiologic studies suggest that early chemoprophylaxis is associated with decreased risk of transmission of pertussis [<a href="#rid62">62-64</a>]. In the only randomized trial, <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a> was 68 percent efficacious in preventing culture-confirmed pertussis in household contacts [<a href="#rid65">65</a>]. However, there was no difference in duration of respiratory symptoms between the treatment and placebo groups. Twenty percent of household contacts in both groups had symptoms consistent with pertussis before treatment was initiated. A post-hoc analysis excluding these subjects demonstrated no difference in the secondary attack rate between treatment and placebo groups, but the sample size may have been too small to detect a significant difference. Therefore, antimicrobial prophylaxis continues to be recommended for close contacts of patients with pertussis.</p><p class="headingAnchor" id="H19"><span class="h3">Regimen</span><span class="headingEndMark"> — </span>The antibiotic regimens for postexposure prophylaxis are identical to those used for treatment of pertussis  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>) [<a href="#rid1">1,2,62,63</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Immunization</span><span class="headingEndMark"> — </span>We recommend age-appropriate immunization against pertussis for infants, children, adolescents, and adults  (<a class="graphic graphic_figure graphicRef82617 graphicRef58209 graphicRef82634" href="/d/graphic/82617.html" rel="external">figure 1A-C</a>). Immunization against pertussis has dramatically reduced the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpertussis%2Fsurv-reporting.html&amp;token=qznno9peugsdlmUEpVr8soAoN5hYQoGHSjL1KaG7BPjxRuQNRSNsQv1VQ0FGucMb99i10Ic3ZzHKQlP4E3fRNw%3D%3D&amp;TOPIC_ID=5997" target="_blank">burden of disease</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine immunization</strong> – Routine immunization of infants, children, adolescents, and adults (particularly pregnant women) is the most important preventive strategy [<a href="#rid1">1</a>]. Routine vaccination against pertussis is discussed separately. (See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a> and  <a class="medical medical_review" href="/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention", section on 'Vaccination'</a> and  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'</a> and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunization of contacts</strong> – Close contacts of the index case who are unimmunized or underimmunized should have pertussis immunization initiated or continued according to the recommended schedule [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age", section on 'United States'</a> and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Schedules'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunization after pertussis infection</strong> – Well-documented pertussis infection (eg, a positive culture for <em>B. pertussis</em> or an epidemiologic link to a culture-positive case) is likely to confer immunity against pertussis [<a href="#rid66">66</a>]. However, the duration of immunity is unknown, and pertussis infection can reoccur as immunity wanes. We agree with the American Academy of Pediatrics recommendation that children who have had well-documented pertussis disease complete age-appropriate immunization with an acellular pertussis-containing vaccine (either diphtheria toxoid, tetanus toxoid and acellular (DTaP) vaccine or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis [Tdap] vaccine) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age", section on 'United States'</a> and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Schedules'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal immunization</strong> – Early neonatal immunization is a strategy that is being studied [<a href="#rid67">67-69</a>] but is not yet recommended.</p><p></p><p class="headingAnchor" id="H90991111"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>Infection control measures for hospitalized patients are discussed above. (See <a class="local">'Hospitalization'</a> above.)</p><p>In the outpatient setting, symptomatic contacts of the index case of pertussis should avoid contact with high-risk individuals until they have completed five days of antimicrobial prophylaxis [<a href="#rid61">61</a>]. It is not necessary for asymptomatic contacts who are receiving antimicrobial prophylaxis to avoid contact with high-risk individuals. </p><p class="headingAnchor" id="H24"><span class="h2">Return to school or day care</span><span class="headingEndMark"> — </span>Because of the high risk of transmission, infected children should be excluded from school or day care until they have completed five days of effective antimicrobial therapy (regardless of the antimicrobial agent), or, if they are not treated, 21 days after the onset of symptoms [<a href="#rid2">2</a>]. Contacts of an infected child should be closely observed for development of respiratory symptoms for at least 21 days after the last contact with the infected individual.</p><p class="headingAnchor" id="H3722692503"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109611.html" rel="external">"Society guideline links: Pertussis"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16553.html" rel="external">"Patient education: Whooping cough (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Indications for hospitalization include increased work of breathing, pneumonia, inability to feed, cyanosis, apnea, seizures, and age &lt;4 months (given concerns for rapid deterioration). For infants &lt;4 months, hospitalization at a major medical center with a pediatric intensive care unit may be desirable because clinical decline may occur rapidly and without warning. (See <a class="local">'Hospitalization'</a> above and <a class="local">'Special population: Infants &lt;4 months'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supportive care is the mainstay of treatment for pertussis in infants and children. Particular attention must be paid to the child's fluid and nutritional status. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Known triggers for coughing paroxysms (eg, exercise, cold temperatures, nasopharyngeal suctioning) should be avoided if possible. Symptomatic treatments including bronchodilators, corticosteroids, antihistamines, and antitussive agents have not been proven to be beneficial in improving the cough in patients with pertussis. (See <a class="local">'Management of cough'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When administered early in the course, antimicrobial therapy can shorten the duration of symptoms and decrease transmission to close contacts. Early initiation of antimicrobial therapy entails a high degree of clinical suspicion, since laboratory confirmation of the diagnosis can take as long as a week. (See  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the ability of antibiotics to eradicate pertussis from the nasopharynx, we recommend antimicrobial treatment for infants and children who have <em>Bordetella pertussis</em> isolated from cultures or have positive polymerase chain reaction for pertussis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also recommend antimicrobial treatment for patients with a clinical diagnosis of pertussis who have had symptoms for less than 21 days (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend macrolide antibiotics for the treatment and prophylaxis of pertussis  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">Trimethoprim-sulfamethoxazole</a> may be an alternative for patients who have a contraindication to or cannot tolerate macrolide agents  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>). (See <a class="local">'Choice of regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infantile hypertrophic pyloric stenosis should be considered in young infants who develop vomiting within one month of therapy with a macrolide antibiotic given in the first month of life. (See <a class="local">'Choice of regimen'</a> above and  <a class="medical medical_review" href="/d/html/5890.html" rel="external">"Infantile hypertrophic pyloric stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest antimicrobial prophylaxis for household and close contacts of the index case and for individuals at high risk for severe or complicated pertussis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Postexposure prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The regimen for antimicrobial prophylaxis is the same as that for treatment  (<a class="graphic graphic_table graphicRef75339" href="/d/graphic/75339.html" rel="external">table 1</a>). Antimicrobial prophylaxis should be initiated within 21 days of onset of cough in the index case. (See <a class="local">'Regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For incompletely immunized children with well-documented pertussis infection, we suggest completion of immunization with an acellular pertussis-containing vaccine (either diphtheria toxoid, tetanus toxoid, and acellular pertussis [DTaP] vaccine or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis [Tdap] vaccine) rather than diphtheria toxoid and tetanus toxoid vaccine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Immunization'</a> above and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"</a> and  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with pertussis or suspected pertussis may return to school or day care after they have completed five days of effective antimicrobial therapy or, if they are not treated, 21 days after the onset of symptoms. (See <a class="local">'Return to school or day care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.</a></li><li class="breakAll">American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.578.</li><li><a class="nounderline abstract_t">Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis 1999; 28:1238.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:1283.</a></li><li class="breakAll">Cherry JD, Harrison R, Bradley JS, et al. Pertussis in young infants -- Guidance for clinicians. May 2010, updated June 2011. www.cdph.ca.gov/HealthInfo/discond/Pages/Pertussis.aspx (Accessed on July 10, 2015).</li><li><a class="nounderline abstract_t">Wang K, Bettiol S, Thompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2014; :CD003257.</a></li><li><a class="nounderline abstract_t">Mertsola J, Viljanen MK, Ruuskanen O. Salbutamol in the treatment of whooping cough. Scand J Infect Dis 1986; 18:593.</a></li><li><a class="nounderline abstract_t">Krantz I, Norrby SR, Trollfors B. Salbutamol vs. placebo for treatment of pertussis. Pediatr Infect Dis 1985; 4:638.</a></li><li><a class="nounderline abstract_t">Roberts I, Gavin R, Lennon D. Randomized controlled trial of steroids in pertussis. Pediatr Infect Dis J 1992; 11:982.</a></li><li><a class="nounderline abstract_t">Zoumboulakis D, Anagnostakis D, Albanis V, Matsaniotis N. Steroids in treatment of pertussis. A controlled clinical trial. Arch Dis Child 1973; 48:51.</a></li><li><a class="nounderline abstract_t">Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.</a></li><li><a class="nounderline abstract_t">Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007; :CD004404.</a></li><li><a class="nounderline abstract_t">Kwantes W, Joynson DH, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149.</a></li><li><a class="nounderline abstract_t">Henry R, Dorman D, Skinner J, Mellis C. Limitations of erythromycin in whooping cough. Med J Aust 1981; 2:108.</a></li><li><a class="nounderline abstract_t">Riitta H. The effect of early erythromycin treatment on the infectiousness of whooping cough patients. Acta Paediatr Scand 1982; 298:10.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Guidelines for the control of pertussis outbreaks. www.cdc.gov/pertussis/outbreaks/guide/index.html (Accessed on July 10, 2015).</li><li><a class="nounderline abstract_t">Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.</a></li><li><a class="nounderline abstract_t">Bass JW. Pertussis: current status of prevention and treatment. Pediatr Infect Dis 1985; 4:614.</a></li><li><a class="nounderline abstract_t">Hoppe JE. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. Pediatr Infect Dis J 1992; 11:189.</a></li><li><a class="nounderline abstract_t">Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768.</a></li><li><a class="nounderline abstract_t">Steketee RW, Wassilak SG, Adkins WN Jr, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis 1988; 157:434.</a></li><li><a class="nounderline abstract_t">Bergquist SO, Bernander S, Dahnsjö H, Sundelöf B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.</a></li><li><a class="nounderline abstract_t">Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr 2016; 105:39.</a></li><li><a class="nounderline abstract_t">Liu X, Wang Z, Zhang J, et al. Pertussis Outbreak in a Primary School in China: Infection and Transmission of the Macrolide-resistant Bordetella pertussis. Pediatr Infect Dis J 2018; 37:e145.</a></li><li><a class="nounderline abstract_t">Fu P, Wang C, Tian H, et al. Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance. Pediatr Infect Dis J 2019; 38:370.</a></li><li><a class="nounderline abstract_t">Mi YM, Hua CZ, Fang C, et al. Effect of Macrolides and β-lactams on Clearance of Bordetella pertussis in the Nasopharynx in Children With Whooping Cough. Pediatr Infect Dis J 2021; 40:87.</a></li><li><a class="nounderline abstract_t">Shahcheraghi F, Nakhost Lotfi M, Nikbin VS, et al. The First Macrolide-Resistant Bordetella pertussis Strains Isolated From Iranian Patients. Jundishapur J Microbiol 2014; 7:e10880.</a></li><li><a class="nounderline abstract_t">Mirzaei B, Bameri Z, Babaei R, Shahcheraghi F. Isolation of High Level Macrolide Resistant Bordetella pertussis Without Transition Mutation at Domain V in Iran. Jundishapur J Microbiol 2015; 8:e18190.</a></li><li><a class="nounderline abstract_t">Guillot S, Descours G, Gillet Y, et al. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis 2012; 18:966.</a></li><li><a class="nounderline abstract_t">Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999; 354:2101.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin--Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep 1999; 48:1117.</a></li><li><a class="nounderline abstract_t">Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics 2015; 135:483.</a></li><li><a class="nounderline abstract_t">Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001; 139:380.</a></li><li><a class="nounderline abstract_t">Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002; 156:647.</a></li><li><a class="nounderline abstract_t">Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ 2014; 348:g1908.</a></li><li><a class="nounderline abstract_t">Hauben M, Amsden GW. The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental? Drug Saf 2002; 25:929.</a></li><li><a class="nounderline abstract_t">Friedman DS, Curtis CR, Schauer SL, et al. Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol 2004; 25:967.</a></li><li><a class="nounderline abstract_t">Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:e96.</a></li><li><a class="nounderline abstract_t">Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001; 20:1149.</a></li><li><a class="nounderline abstract_t">Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996; 129:761.</a></li><li><a class="nounderline abstract_t">Baće A, Zrnić T, Begovac J, et al. Short-term treatment of pertussis with azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis 1999; 18:296.</a></li><li><a class="nounderline abstract_t">Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection 1978; 6:228.</a></li><li><a class="nounderline abstract_t">Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep 1991; 40:1.</a></li><li><a class="nounderline abstract_t">Cherry JD, Wendorf K, Bregman B, et al. An Observational Study of Severe Pertussis in 100 Infants ≤120 Days of Age. Pediatr Infect Dis J 2018; 37:202.</a></li><li><a class="nounderline abstract_t">Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326.</a></li><li><a class="nounderline abstract_t">Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328.</a></li><li><a class="nounderline abstract_t">Winter K, Zipprich J, Harriman K, et al. Risk Factors Associated With Infant Deaths From Pertussis: A Case-Control Study. Clin Infect Dis 2015; 61:1099.</a></li><li><a class="nounderline abstract_t">Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003; 143:576.</a></li><li><a class="nounderline abstract_t">Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med 2000; 26:1512.</a></li><li class="breakAll">American Academy of Pediatrics. Pertussis in young infants. www.aap-ca.org/clinical/pertussis/pertussis_in_young_infants.html (Accessed on February 14, 2012).</li><li><a class="nounderline abstract_t">Rowlands HE, Goldman AP, Harrington K, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126:e816.</a></li><li><a class="nounderline abstract_t">Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 2004; 114:e264.</a></li><li><a class="nounderline abstract_t">Grzeszczak MJ, Churchwell KB, Edwards KM, Pietsch J. Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure. Pediatr Crit Care Med 2006; 7:580.</a></li><li><a class="nounderline abstract_t">Donoso AF, Cruces PI, Camacho JF, et al. Exchange transfusion to reverse severe pertussis-induced cardiogenic shock. Pediatr Infect Dis J 2006; 25:846.</a></li><li><a class="nounderline abstract_t">Nieves D, Bradley JS, Gargas J, et al. Exchange blood transfusion in the management of severe pertussis in young infants. Pediatr Infect Dis J 2013; 32:698.</a></li><li><a class="nounderline abstract_t">Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 2003; 112:1274.</a></li><li><a class="nounderline abstract_t">Murray EL, Nieves D, Bradley JS, et al. Characteristics of severe Bordetella pertussis infection among infants ≤90 days of age admitted to pediatric intensive care units - Southern California, September 2009-June 2011. J Pediatric Infect Dis Soc 2013; 2:1.</a></li><li><a class="nounderline abstract_t">Kuperman A, Hoffmann Y, Glikman D, et al. Severe pertussis and hyperleukocytosis: is it time to change for exchange? Transfusion 2014; 54:1630.</a></li><li><a class="nounderline abstract_t">Chen HN, Lee ML, Tsao LY. Exchange transfusion using peripheral vessels is safe and effective in newborn infants. Pediatrics 2008; 122:e905.</a></li><li><a class="nounderline abstract_t">Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.</a></li><li><a class="nounderline abstract_t">Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 1998; 120:143.</a></li><li><a class="nounderline abstract_t">De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995; 14:969.</a></li><li><a class="nounderline abstract_t">Yeh SH. Pertussis: persistent pathogen, imperfect vaccines. Expert Rev Vaccines 2003; 2:113.</a></li><li><a class="nounderline abstract_t">Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. Pediatrics 1999; 104:e42.</a></li><li><a class="nounderline abstract_t">Platt L, Thun M, Harriman K, Winter K. A Population-Based Study of Recurrent Symptomatic Bordetella pertussis Infections in Children in California, 2010-2015. Clin Infect Dis 2017; 65:2099.</a></li><li><a class="nounderline abstract_t">Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655.</a></li><li><a class="nounderline abstract_t">Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003; 111:1042.</a></li><li><a class="nounderline abstract_t">Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008; 153:327.</a></li></ol></div><div id="topicVersionRevision">Topic 5997 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340941" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340941" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451159" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371944" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pertussis--United States, 2001-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371944" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pertussis--United States, 2001-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25243777" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Symptomatic treatment of the cough in whooping cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3810052" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Salbutamol in the treatment of whooping cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3909118" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Salbutamol vs. placebo for treatment of pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1454452" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized controlled trial of steroids in pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4568265" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Steroids in treatment of pertussis. A controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584314" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical course of pertussis in immunized children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636756" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotics for whooping cough (pertussis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300227" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272070" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Limitations of erythromycin in whooping cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The effect of early erythromycin treatment on the infectiousness of whooping cough patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11837909" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pertussis--United States, 1997-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11837909" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pertussis--United States, 1997-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788498" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical practice. Pertussis--not just for kids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3878499" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pertussis: current status of prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1565532" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4310467" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antimicrobial treatment of pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257783" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2885802" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341383" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29088029" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pertussis Outbreak in a Primary School in China: Infection and Transmission of the Macrolide-resistant Bordetella pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882726" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021592" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of Macrolides andβ-lactams on Clearance of Bordetella pertussis in the Nasopharynx in Children With Whooping Cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371806" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The First Macrolide-Resistant Bordetella pertussis Strains Isolated From Iranian Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26396713" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Isolation of High Level Macrolide Resistant Bordetella pertussis Without Transition Mutation at Domain V in Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608348" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Macrolide-resistant Bordetella pertussis infection in newborn girl, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10609814" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634345" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin--Knoxville, Tennessee, 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25687145" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Azithromycin in early infancy and pyloric stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11562617" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12090829" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24618148" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381214" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15566032" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231980" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740322" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917247" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10385021" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Short-term treatment of pertussis with azithromycin in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/215555" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1865873" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28737623" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : An Observational Study of Severe Pertussis in 100 Infants≤120 Days of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831828" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558873" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pathology and pathogenesis of fatal Bordetella pertussis infection in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26082502" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk Factors Associated With Infant Deaths From Pertussis: A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14615725" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11126265" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is leukocytosis a predictor of mortality in severe pertussis infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11126265" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Is leukocytosis a predictor of mortality in severe pertussis infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20819895" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286267" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16878048" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940848" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Exchange transfusion to reverse severe pertussis-induced cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407101" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Exchange blood transfusion in the management of severe pertussis in young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654596" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26619437" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Characteristics of severe Bordetella pertussis infection among infants≤90 days of age admitted to pediatric intensive care units - Southern California, September 2009-June 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330004" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Severe pertussis and hyperleukocytosis: is it time to change for exchange?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779255" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Exchange transfusion using peripheral vessels is safe and effective in newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22108587" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593483" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584364" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Field effectiveness of erythromycin prophylaxis to prevent pertussis within families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12901603" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pertussis: persistent pathogen, imperfect vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506267" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29099909" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A Population-Based Study of Recurrent Symptomatic Bordetella pertussis Infections in Children in California, 2010-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410769" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728086" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Immunogenicity of a three-component acellular pertussis vaccine administered at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534242" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
